The ADNI4 (Alzheimer's Disease Neuroimaging Initiative 4) Protocol is the fifth wave of a North American multicenter observational study launched in 2004, sponsored by the National Institute on Aging and the National Institutes of Health. The primary goal of this study is to discover, optimize, standardize, and validate clinical biomarkers used in Alzheimer's disease research and clinical trials. This study seeks to enroll individuals ages 55-90, willing and able to undergo yearly test procedures including cognitive tests, questionnaires, brain imaging, blood draws, and spinal taps. Eligible individuals may have normal cognition with no memory concerns, or have memory concerns and diagnosis of mild cognitive impairment or dementia due to Alzheimer’s disease. Participants will be evaluated on a yearly basis, for 2 to 4 years.

(PI: Maryam Beigi, MD, Easton Center's Katherine and Benjamin Kagan Alzheimer's Disease Treatment Development Program)

Contact: Lorena Macias at (310) 794-6191 or LorenaMacias@mednet.ucla.edu to participate in this study or for more information.

English PDF  

Sponsor: University of Southern California

ClinicalTrials.gov Identifier: NCT05617014


Mild Cognitive Impairment (MCI)
Alzheimer's Disease (AD)

Study Type: Observational

Study Design: 

Observational Model: Cohort
Time Perspective: Prospective

Official Title: Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4) Protocol

Length of Study: Participants will be evaluated on a yearly basis, for 2 to 4 years.

Source: ClinicalTrials.gov

Ages Eligible for Study: 55 Years to 90 Years

Genders Eligible for Study: Both